Phase II Trial of Nilotinib in Patients With Metastatic Malignant Melanoma Harboring KIT Gene Aberration: A Multicenter Trial of Korean Cancer Study Group (UN10-06)

BACKGROUND. KIT has been suggested to be a potential therapeutic target for malignant melanoma. We evaluated the antitumor activity and safety of the KIT inhibitor nilotinib in metastatic melanoma patients harboring KIT gene mutations or amplifications. METHODS. We conducted a phase II multicenter t...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncologist
Hlavní autoři: Lee, Su Jin, Kim, Tae Min, Kim, Yu Jung, Jang, Kee-Taek, Lee, Hyo Jin, Lee, Soon Nam, Ahn, Mi Sun, Hwang, In Gyu, Lee, Suee, Lee, Moon-Hee, Lee, Jeeyun
Médium: Artigo
Jazyk:Inglês
Vydáno: AlphaMed Press 2015
Témata:
Melanoma and Cutaneous Malignancies
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4718426/
https://ncbi.nlm.nih.gov/pubmed/26424760
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2015-0161
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky